1087 related articles for article (PubMed ID: 20979473)
21. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
[TBL] [Abstract][Full Text] [Related]
22. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract][Full Text] [Related]
23. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
[TBL] [Abstract][Full Text] [Related]
24. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
Okamoto I; Nakagawa K
Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
[TBL] [Abstract][Full Text] [Related]
25. Crizotinib--latest champion in the cancer wars?
Hallberg B; Palmer RH
N Engl J Med; 2010 Oct; 363(18):1760-2. PubMed ID: 20979477
[No Abstract] [Full Text] [Related]
26. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H
Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
28. [A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors
and Chemotherapy].
Wang J; Xu X; Sun Y; Li H
Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):372-376. PubMed ID: 34034462
[TBL] [Abstract][Full Text] [Related]
29. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
[TBL] [Abstract][Full Text] [Related]
30. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.
Yoshida A; Tsuta K; Watanabe S; Sekine I; Fukayama M; Tsuda H; Furuta K; Shibata T
Lung Cancer; 2011 Jun; 72(3):309-15. PubMed ID: 21036415
[TBL] [Abstract][Full Text] [Related]
31. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
32. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
Sanders HR; Li HR; Bruey JM; Scheerle JA; Meloni-Ehrig AM; Kelly JC; Novick C; Albitar M
Cancer Genet; 2011 Jan; 204(1):45-52. PubMed ID: 21356191
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
[TBL] [Abstract][Full Text] [Related]
34. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.
Zhang Z; Shiratsuchi H; Palanisamy N; Nagrath S; Ramnath N
J Thorac Oncol; 2017 Feb; 12(2):397-402. PubMed ID: 27507192
[TBL] [Abstract][Full Text] [Related]
35. Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.
Radtke J; Rezaie SG; Kugler Ch; Zabel P; Schultz H; Vollmer E; Goldmann T; Lang DS
Rom J Morphol Embryol; 2010; 51(4):647-53. PubMed ID: 21103621
[TBL] [Abstract][Full Text] [Related]
36. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
37. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
38. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
40. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]